Work

Mechanistic interplay between aflatoxin B1 and tissue inhibitor of metalloproteinase-3 in hepatocellular carcinoma

Year: 2025

Type: editorial

Abstract: Hepatocellular carcinoma (HCC) is a major global health challenge, particularly in regions with high aflatoxin B1 (AFB1) exposure. This editorial explores the mechanistic interplay between AFB1 and tissue inhibitor of metalloproteinase-3 (TIMP-3) in AFB1-related HCC. TIMP-3, frequently downregulated in HCC due to promoter methylation, is linked to increased tumor aggressiveness and poor prognosis. We propose that AFB1 induces epigenetic silencing of TIMP-3, potentially via DNA adducts and oxidative stress, exacerbating AFB1-related HCC progression. This AFB1-TIMP-3 axis highlights TIMP-3’s potential as a prognostic biomarker and therapeutic target. Future research should focus on elucidating these molecular pathways and integrating TIMP-3 into clinical practice for early detection and targeted therapies in AFB1-prevalent regions.

Source: World Journal of Hepatology

DOI: 10.4254/wjh.v17.i10.109391

Authors: Yan Luo, Li-Juan Wang, Cheng-Long Wang

Language: English

Topic: Protease and Inhibitor Mechanisms

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Bill and Melinda Gates Foundation, Johns Hopkins University, University of Pittsburgh, National Institutes of Health

Awards: G8232721138, G9000052321